Zyngenia, Inc.
Founded in 2008, Zyngenia, Inc. is a privately held biotherapeutics
company focused on the development of next-generation multi-specific
antibody-based therapeutics. The Company uses proprietary patented
technology to engineer single molecular entities that may interact with two
or more targets.
The multiple target strategy may create opportunities for innovative
therapeutics with new mechanisms of action that are not achievable with
single specificity antibodies. The company will initially focus its Zybody
development on therapies for various cancers and autoimmune disorders while
emphasizing cost-effective discovery, manufacturing and clinical development
practices.
www.zyngenia.com
|